Inflammatory bowel disease and gastrointestinal malignancies - risks, incidence and management

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10365172" target="_blank" >RIV/00216208:11110/17:10365172 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.prolekare.cz/linkout/62075" target="_blank" >http://www.prolekare.cz/linkout/62075</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14735/amgh2017388" target="_blank" >10.14735/amgh2017388</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Inflammatory bowel disease and gastrointestinal malignancies - risks, incidence and management

Popis výsledku v původním jazyce

Inflammatory bowel disease (IBD) is characterized as an immunomediated chronic inflammation in Crohn&apos;s disease and ulcerative colitis. Although the exact cause of IBD is not entirely clear, an abnormal reaction of the immune system towards physiological microbiota in the colon and small bowel is suspected. IBD has long been associated with an increased risk of malignancies. The main risk is IBD-associated colorectal cancer, which is caused by chronic inflammation, followed by other cancers (including extraintestinal cancers) that develop as a result of the inflammation and subsequent treatment with immunosuppressors/ /biologics. Recent advances in immunosuppressive therapies have significantly improved prognosis as well as quality of life of IBD patients. However, longer survival means prolonged exposure to chronic inflammation as well as to immunosupression (biologics), which translates into a higher risk of cancer development. Therefore, in addition to anti-inflammatory therapies, current strategies for the management of IBD patients also include cancer prevention and surgery, systemic therapy, radiotherapy, and hormonal therapy. The current paper describes the major risk factors of malignancy in IBD patients, and provides an overview of the most commonly occurring IBD-associated gastrointestinal cancers and their management.

Název v anglickém jazyce

Inflammatory bowel disease and gastrointestinal malignancies - risks, incidence and management

Popis výsledku anglicky

Inflammatory bowel disease (IBD) is characterized as an immunomediated chronic inflammation in Crohn&apos;s disease and ulcerative colitis. Although the exact cause of IBD is not entirely clear, an abnormal reaction of the immune system towards physiological microbiota in the colon and small bowel is suspected. IBD has long been associated with an increased risk of malignancies. The main risk is IBD-associated colorectal cancer, which is caused by chronic inflammation, followed by other cancers (including extraintestinal cancers) that develop as a result of the inflammation and subsequent treatment with immunosuppressors/ /biologics. Recent advances in immunosuppressive therapies have significantly improved prognosis as well as quality of life of IBD patients. However, longer survival means prolonged exposure to chronic inflammation as well as to immunosupression (biologics), which translates into a higher risk of cancer development. Therefore, in addition to anti-inflammatory therapies, current strategies for the management of IBD patients also include cancer prevention and surgery, systemic therapy, radiotherapy, and hormonal therapy. The current paper describes the major risk factors of malignancy in IBD patients, and provides an overview of the most commonly occurring IBD-associated gastrointestinal cancers and their management.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Gastroenterologie a hepatologie

ISSN

1804-7874

e-ISSN

—

Svazek periodika

71

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

388-393

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85035787004